Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.

[1]  G. Broadwater,et al.  Creation of an individualized algorithm for venous thromboembolism prophylaxis on a gynecologic oncology service , 2021, Gynecologic Oncology.

[2]  A. Weaver,et al.  Risk based triage for complex surgery in ovarian cancer: ready for prime time , 2021, Gynecologic Oncology.

[3]  Hongyu Peng,et al.  Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial , 2021, Gynecologic Oncology.

[4]  A. Italiano,et al.  Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study , 2021, Gynecologic Oncology.

[5]  B. Monk,et al.  Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma , 2021, Gynecologic Oncology.

[6]  M. Shahin,et al.  Racial determinants of treatment delays in gynecologic malignancies , 2021, Gynecologic Oncology.

[7]  A. Sood,et al.  Frailty repels the knife: the impact of frailty index on surgical intervention and outcomes , 2021, Gynecologic Oncology.

[8]  Jingru Zhang,et al.  Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): a multicenter, randomized, controlled, open-label, phase II trial , 2021, Gynecologic Oncology.

[9]  A. Oza,et al.  Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1 , 2021, Gynecologic Oncology.

[10]  A. Italiano,et al.  Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study , 2021, Gynecologic Oncology.

[11]  M. Hammer,et al.  Priority assessment for women with recurrent ovarian cancer: a pilot study , 2021, Gynecologic Oncology.

[12]  G. Lou,et al.  Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial , 2021, Gynecologic Oncology.

[13]  S. Domchek,et al.  Innovation in germline and somatic tumor testing pathways for ovarian cancer patients , 2021, Gynecologic Oncology.

[14]  A. Jazaeri,et al.  ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma , 2021, Gynecologic Oncology.

[15]  C. Choi,et al.  KGOG 3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage epithelial ovarian cancer , 2021, Gynecologic Oncology.

[16]  M. Hacker,et al.  Patients with endometrial intraepithelial neoplasia do not need routine lymph node sampling , 2021, Gynecologic Oncology.

[17]  G. Parham,et al.  Randomized control trial of thermal ablation of the cervix in women living with the human immunodeficiency virus in Zambia , 2021, Gynecologic Oncology.

[18]  Yong-wen Huang,et al.  Comparative analysis of quality of life for three different adjuvant treatment modality in early stage cervical cancer: an analysis from STARS study , 2021, Gynecologic Oncology.

[19]  V. Gebski,et al.  Complete pathological response following levonorgestrel intrauterine device in clinically stage I endometrial adenocarcinoma: Results of a randomized clinical trial , 2021, Gynecologic Oncology.

[20]  A. Caughey,et al.  Hysterectomy with a general gynecologist versus gynecologic-oncologist in the setting of complex atypical hyperplasia: a cost-effectiveness analysis , 2021, Gynecologic Oncology.

[21]  G. Lou,et al.  Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial , 2021, Gynecologic Oncology.

[22]  B. Rimel.  A randomized, phase ii study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer , 2021, Gynecologic Oncology.

[23]  M. Schlumbrecht,et al.  Factors associated with completion of intracavitary brachytherapy: do socio-demographic factors play a role? , 2021, Gynecologic Oncology.

[24]  Ping Wang,et al.  An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial , 2021, Gynecologic Oncology.

[25]  L. Chambers,et al.  Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: the MIID-SOC trial , 2021, Gynecologic Oncology.

[26]  T. Conrads,et al.  Eliminating racial disparities in endometrial cancer clinical trial enrollment in the Deep South: a pathway to equity , 2021, Gynecologic Oncology.

[27]  G. Baiocchi,et al.  A proof-of-concept randomized phase 2 non-inferiority trial on simple versus modified radical hysterectomy in IA2-IB1 cervical cancer ≤2cm (LESSER) , 2021, Gynecologic Oncology.

[28]  K. Yonemori,et al.  A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer , 2021, Gynecologic Oncology.

[29]  Gloria S. Huang,et al.  Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer , 2021, Gynecologic Oncology.

[30]  Matthew Anderson,et al.  Routine early screening for chemotherapy-induced hearing loss and other neuropathies in patients undergoing cancer treatment: a pilot study , 2021, Gynecologic Oncology.

[31]  A. Okamoto,et al.  Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39 , 2021, Gynecologic Oncology.

[32]  S. Temkin,et al.  Workplace bullying, harassment and microaggressions: the results of a Women of Gynecologic Oncology (WGO) survey , 2021, Gynecologic Oncology.

[33]  M. Morgan,et al.  Quality of oncologic care and outcomes of patients with endometrial cancer managed at minority-serving hospitals , 2021, Gynecologic Oncology.

[34]  G. Lou,et al.  Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial , 2021, Gynecologic Oncology.

[35]  Richard O. Moore,et al.  A surgical window trial evaluating medroxyprogesterone acetate with or without entinostat in endometrial cancer and validation of biomarkers of cellular response: An NRG Oncology study , 2021, Gynecologic Oncology.

[36]  A. Kurian,et al.  Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind? , 2021, Gynecologic Oncology.

[37]  M. Frey,et al.  Using health information technology to improve collection of family cancer history: prospective randomized trial of web-based tool in a gynecologic oncology outpatient clinic , 2021, Gynecologic Oncology.

[38]  M. Frey,et al.  COVID-19 outcomes of patients with gynecologic cancer in New York City: an updated analysis , 2021, Gynecologic Oncology.

[39]  S. Blank,et al.  Does COVID-19 compromise SGO member well-being? , 2021, Gynecologic Oncology.

[40]  B. Monk,et al.  Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer , 2021, Gynecologic Oncology.

[41]  D. Cohn,et al.  Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. , 2021, Gynecologic oncology.

[42]  R. Kristeleit,et al.  Rucaparib versus chemotherapy in patients with advanced , relapsed ovarian cancer and a deleterious BRCA mutation : Efficacy and safety from ARIEL 4 , a randomized phase III study Presenting , 2021 .

[43]  A. Jazaeri,et al.  The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice , 2021 .

[44]  S. Kannan,et al.  Phase III Randomized Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) versus Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER): Final Analysis , 2020 .

[45]  Richard O. Moore,et al.  Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab , 2020, Gynecologic Oncology.

[46]  B. Monk,et al.  Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. , 2019, Journal of Clinical Oncology.